SecSonar.com

Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Coherus Oncology, Inc. (CHRS) is a Biotechnology company based in US with a market capitalization of $198.7M. Revenue declined 84.2% year-over-year and free cash flow was negative at -$138.5M. This page tracks CHRS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 228 employees · IPO Nov 6, 2014

Valuation

Valuation & price

$1.57 · as of May 17, 2026 · -37.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.26

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.28$1.51$0.75Jul 25Dec 25Jun 26Jul 7, 25$0.75Jul 9, 25$0.87Jul 11, 25$0.88Jul 15, 25$0.85Jul 17, 25$0.90Jul 21, 25$0.89Jul 23, 25$0.98Jul 25, 25$1.04Jul 29, 25$1.01Jul 31, 25$0.94Aug 4, 25$0.87Aug 6, 25$0.92Aug 8, 25$0.82Aug 12, 25$0.92Aug 14, 25$1.02Aug 19, 25$1.07Aug 21, 25$1.13Aug 25, 25$1.17Aug 27, 25$1.14Aug 29, 25$1.16Sep 3, 25$1.26Sep 5, 25$1.29Sep 9, 25$1.35Sep 11, 25$1.33Sep 15, 25$1.27Sep 17, 25$1.35Sep 19, 25$1.61Sep 23, 25$1.56Sep 25, 25$1.45Sep 29, 25$1.70Oct 2, 25$1.66Oct 6, 25$1.70Oct 8, 25$1.76Oct 10, 25$1.67Oct 14, 25$1.70Oct 16, 25$1.71Oct 20, 25$1.79Oct 22, 25$1.68Oct 24, 25$1.65Oct 28, 25$1.74Oct 30, 25$1.70Nov 3, 25$1.60Nov 5, 25$1.57Nov 7, 25$1.34Nov 11, 25$1.35Nov 14, 25$1.19Nov 18, 25$1.21Nov 20, 25$1.10Nov 24, 25$1.28Nov 26, 25$1.31Dec 1, 25$1.27Dec 3, 25$1.22Dec 5, 25$1.20Dec 9, 25$1.29Dec 11, 25$1.43Dec 15, 25$1.39Dec 17, 25$1.35Dec 19, 25$1.36Dec 23, 25$1.32Dec 26, 25$1.33Dec 31, 25$1.42Jan 5, 26$1.44Jan 7, 26$1.43Jan 9, 26$1.69Jan 13, 26$1.70Jan 15, 26$1.66Jan 20, 26$1.55Jan 22, 26$1.59Jan 26, 26$2.28Jan 28, 26$2.22Jan 30, 26$2.16Feb 3, 26$2.22Feb 5, 26$2.09Feb 9, 26$2.06Feb 11, 26$2.04Feb 17, 26$1.61Feb 19, 26$1.71Feb 23, 26$1.62Feb 25, 26$1.68Feb 27, 26$1.67Mar 3, 26$1.65Mar 5, 26$1.76Mar 9, 26$1.93Mar 11, 26$1.78Mar 13, 26$1.63Mar 17, 26$1.68Mar 19, 26$1.61Mar 23, 26$1.64Mar 25, 26$1.77Mar 27, 26$1.63Apr 1, 26$1.74Apr 6, 26$1.67Apr 8, 26$1.70Apr 10, 26$1.68Apr 14, 26$1.80Apr 16, 26$1.90Apr 20, 26$1.99Apr 22, 26$1.80Apr 24, 26$1.75Apr 28, 26$1.77Apr 30, 26$1.78May 4, 26$1.73May 6, 26$1.75May 8, 26$1.75May 12, 26$1.71May 15, 26$1.57May 19, 26$1.48May 21, 26$1.57May 26, 26$1.64May 28, 26$1.65Jun 1, 26$1.57Jun 3, 26$1.47Jun 5, 26$1.45Jun 9, 26$1.42Jun 11, 26$1.42Jun 15, 26$1.36Jun 17, 26$1.39Jun 22, 26$1.48Jun 24, 26$1.52Jun 30, 26$1.44
$0.7552-week range$2.51
Loading valuation history…

Fundamentals

Key fundamentals

$198.7M

Market cap

-84.2%

Revenue growth (YoY)

57.9%

Gross margin

-$138.5M

Free cash flow (USD)

-$131.8M

Net debt

Net cash position

5.1%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$190.1MFY 2017$1.6MFY 2018$1.6MFY 2019$356.1MFY 2020$475.8MFY 2021$326.6MFY 2022$211.0MFY 2023$257.2MFY 2024$267.0MFY 2025$42.2M
$190.1M$42.2M

Free cash flow by year

2016 → 2025

FY 2016$-259.1MFY 2017$-204.9MFY 2018$-160.1MFY 2019$15.5MFY 2020$146.9MFY 2021$-38.7MFY 2022$-243.2MFY 2023$-175.2MFY 2024$-20.4MFY 2025$-138.5M
-$259.1M-$138.5M

Gross margin by year

2021 → 2025

FY 202182.4%FY 202266.8%FY 202338.2%FY 202456.0%FY 202557.9%
82.4%57.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAccounting Firm ChangeJun 15, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 1, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing

Questions

Frequently asked questions

What is Coherus Oncology, Inc.'s market cap?

Coherus Oncology, Inc. (CHRS) has a market capitalization of $198.7M.

What is CHRS's P/E ratio?

A meaningful P/E ratio is not available for CHRS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CHRS's price-to-book (P/B) ratio?

CHRS trades at 3.26 times book value per share.

Are insiders buying CHRS stock?

SEC Form 4 filings show no open-market insider buys at Coherus Oncology, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

TNXP

Tonix Pharmaceuticals Holding Corp.

$198M

ARTV

Artiva Biotherapeutics, Inc.

$193.8M

IPSC

Century Therapeutics, Inc.

$205.2M

RNAC

Cartesian Therapeutics, Inc.

$212.4M

SRZN

Surrozen, Inc.

$184.8M

NBP

NovaBridge Biosciences

$213.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.